Compositions and methods for treating fibrosis

Patent metadata

Field	Value
Publication number	US-10245298-B2
Application number	US-201715460151-A
Country	US
Kind code	B2
Filing date	Mar 15, 2017
Priority date	Sep 18, 2014
Publication date	Apr 2, 2019
Grant date	Apr 2, 2019

Abstract

The invention provides methods for treating fibrosis and/or cancer in a subject in need thereof. The methods include providing a composition comprising an inhibitor of IL-4/IL-13 receptor function and administering an effective amount of the composition to the subject to treat fibrosis and/or cancer.

First claim

What is claimed is:

1. A pharmaceutical composition comprising: a IL-4/IL-13 receptor inhibitor; and (ii) a pharmaceutically acceptable carrier, wherein the IL-4/IL-13 receptor inhibitor is CSRM53567 comprising of the amino acid sequence Tyr-Cys-Asp-Asp-Phe-Val-Gly-Ser-Phe-Asp-Cys-Tyr (SEQ ID NO: 1).

2. The composition of claim 1 , wherein the IL-4/IL-13 receptor inhibitor is attached to moieties that result in PEGylation, glycosylation, lipidation, acetylation, amidation, end-capping modification, adding cyano groups, phosphorylation, or cyclization of the inhibitor.

3. The composition of claim 2 , wherein the end-capping modification comprises acetylation at the N-terminus, N-terminal acylation, or N-terminal formylation.

4. The composition of claim 2 , wherein the end-capping modification comprises amidation at the C-terminus, introduction of C-terminal alcohol, aldehyde, ester, or thioester moieties.

5. The composition of claim 1 , wherein the IL-4/IL-13 receptor inhibitor is attached to moieties that result in extension of half-life of the inhibitor.

6. The composition of claim 5 , wherein the moieties that result in extension of half-life of the inhibitor is Fc domain or serum albumin.

Assignees

• Cedars Sinai Medical Center
• Univ Leland Stanford Junior

Inventors

• Murali Ramachandran
• Habtezion Aida
• Pandol Stephen J

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07K14/5406

  IL-4 · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title

• C07K14/5437

  IL-13 · CPC title

• A61K38/10 Primary

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title